Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for its future headquarters in the Research Park at Florida Atlantic Un ...

Philips Ultrasound is laying off 33 employees from its Bothell, Wash. ...

PLANO, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced that its Board of Directors has authorized a share repurchase program of up to $200 million of the Company’s outstanding common stock. “This share repurchase program reflects the confidence of the Board and management in our strategy, financial position, and ability to generate strong free cash flows,” said Payman Khales, Int ...

NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter ...

Summary of Mindray's 3Q25 Earnings Call Company Overview - **Company**: Mindray (300760.SZ) - **Industry**: Medical Technology (Medtech) Key Financial Results - **3Q25 Revenue**: Rmb 9,091 million, an increase of 1.5% year-over-year (yoy), in line with Goldman Sachs estimates (GSe) of Rmb 9,102 million [1] - **Net Profit**: Rmb 2,501 million, a decrease of 19% yoy, missing GSe of Rmb 3,043 million due to higher-than-expected operating expense ratio of 28.7% compared to GSe of 23.7% [1] Revenue Breakdown by Segment - **PMLS (Patient Monitoring and Life Support)**: - Revenue growth of +2.6% yoy - Domestic revenue decline narrowed to -25% in 3Q25 from -57% in 1H25 - Overseas sales grew +14% yoy, accounting for 70% of total PMLS revenue [2] - **Medical Imaging (MI)**: - Revenue growth of +1% yoy - Domestic sales declined -30% yoy while overseas revenue increased +7% yoy [2] - **IVD (In Vitro Diagnostics)**: - Revenue decline of -2.8% yoy - Domestic growth at -22% and overseas growth at +14% [2] Market Dynamics - **Destocking Phase**: The domestic PMLS business is in a destocking phase, with inventory normalization expected to persist into 4Q25, and revenue recovery anticipated in 2026 [2][9] - **IVD Market Challenges**: The domestic IVD market faces pressures from medical insurance reform, leading to declines in testing volume and pricing [2] - **Market Share**: Mindray's market share in chemiluminescence, biochemistry, and coagulation reagents is approximately 10%, indicating potential for growth [2] Management Guidance and Future Outlook - **Destocking Completion**: Management expects the destocking process to be completed by 4Q25, with channel inventory normalizing to around two months [9] - **Overseas Revenue Growth**: The company anticipates overseas revenue to continue outpacing domestic growth, with an increase in the overseas share of total revenue [9] - **Innovation Focus**: Plans to strengthen the product portfolio in surgical and electrophysiology segments, with long-term optimism about consumables for gastrointestinal and respiratory interventions [9] - **Surgical Robotics**: The surgical robotics business is in early stages, with commercialization expected to take several more years [9] Financial Estimates and Price Target - **Revised Estimates**: - 2025E Revenue: Rmb 33,442 million (down 1.1% from previous estimate) - 2026E Revenue: Rmb 36,966 million (down 1.7% from previous estimate) - 2025E Net Profit: Rmb 8,771 million (down 16.8% from previous estimate) [14] - **Price Target**: The 12-month target price is set at Rmb 285, down from Rmb 314, maintaining a Buy rating [13][16] Risks and Challenges - **Key Risks**: - Impact from Value-Based Procurement (VBP) on product pricing - Lower-than-expected penetration into top-tier hospitals in China - Challenges in entering North American and European markets - Patent-related lawsuit risks - Unexpected changes in trade policies [17] Conclusion - Mindray remains a leading medtech device manufacturer in China, with strong growth potential driven by healthcare infrastructure development and overseas expansion. Despite current challenges, the company is positioned for recovery and growth in the coming years, particularly in the context of its low market share and cost-effective product offerings [15]

Conference call and webcast to be held at 4:30 PM ETPOMPANO BEACH, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the quarter fro ...

Core Insights - Integer Holdings has appointed Payman Khales as the new CEO, succeeding Joseph Dziedzic who retired after eight years [2] - The company reported Q3 2025 sales revenue of $468 million, an 8% year-over-year increase, with adjusted earnings per share growing by 25% [3] - Integer's strategic focus is shifting from a manufacturing-centric model to a customer-centric innovation platform [11][12] Leadership Transition - Payman Khales joined Integer in 2018 and previously served as the president of the Cardio & Vascular Business, where he successfully doubled sales over seven years [6] - Khales has a strong background in industrial manufacturing and operations management, having held senior positions at CECO Environmental Corp. and Ingersoll Rand Co. [7] - His vision for Integer emphasizes innovation and collaboration with customers to enhance clinical value in medical technology [7] Business Structure and Global Positioning - Integer operates as a leading Contract Development and Manufacturing Organization (CDMO), providing end-to-end services from product design to supply chain integration [9] - The company has two main business segments: Cardio & Vascular, which is the largest revenue contributor, and Advanced Surgical & Power Solutions, focusing on neuromodulation and implantable battery systems [9][10] - Integer has over 30 manufacturing and R&D centers globally, enhancing its supply chain stability and compliance management [10] Strategic Intent and Industry Impact - The leadership change signifies a strategic restructuring in response to the competitive landscape of the global CDMO market [11] - Integer aims to extend its capabilities from manufacturing to early product development and engineering validation, leveraging a "customer co-innovation" model [12] - The global medical device industry is experiencing a shift towards outsourcing non-core manufacturing to CDMO partners, with the market expected to grow from approximately $15 billion in 2023 to $27 billion by 2030 [13] Future Directions - Under Khales, Integer is likely to enhance investments in digital manufacturing, supply chain transparency, and sustainable operations, aligning with industry trends [13] - The transition positions Integer to evolve from a traditional contract manufacturer to a high-end medical manufacturing platform with innovation incubation capabilities [14] - The leadership change reflects broader structural changes in the medical device manufacturing sector, where OEMs and CDMOs are increasingly collaborating in design and innovation processes [14][15]

Leadership Transition - Integer Holdings Corporation has completed a planned leadership transition with Payman Khales assuming the role of President and CEO, succeeding Joseph Dziedzic who is retiring after eight years [1] - Joseph Dziedzic will continue to serve as an advisor until March 31, 2026, to ensure a smooth transition [1] Executive Background - Payman Khales joined Integer in 2018 as President of the Cardio & Vascular business, where he successfully doubled sales over seven years and improved service levels and profitability [2] - As Chief Operating Officer, Khales oversaw Integer's business units and global operations, enhancing the company's reputation as a strategic partner to medical device companies [2] Vision and Strategy - Khales expressed enthusiasm for the opportunities ahead, focusing on innovation, collaboration with customers, and delivering life-changing medical technologies [3] - He emphasized the importance of creating value through teamwork and leveraging the talents of Integer's associates [3] Company Overview - Integer Holdings Corporation is a leading global medical device contract development and manufacturing organization, serving markets such as cardiac rhythm management and neuromodulation [4] - The company is committed to enhancing patient lives by providing innovative, high-quality products and solutions, with brands including Greatbatch Medical and Lake Region Medical [4]

GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will hold a conference call to review the Company’s third quarter 2025 performance starting at 4:3 ...

Financial Data and Key Metrics Changes - For the second quarter, revenue increased slightly to $5,160,000 compared to $5,130,000 in the previous quarter, marking the sixth consecutive quarter of revenue over $5,000,000 [20][29] - Net income for the quarter increased 27% to $431,000 compared to $340,000 last year, reflecting higher gross profit and lower operating expenses [20][33] - For the first half of fiscal year 2026, total sales reached a record $10,300,000, up from $10,190,000 in the previous year, with net income increasing 36% to $917,000 [23][37] Business Line Data and Key Metrics Changes - Medical market sales increased by 150% year over year to $1,000,000, driven by balloon coating systems shipped to the U.S., Europe, and China [19][22] - Integrated Coatings Systems sales decreased by 24% to $1,530,000, primarily due to a customer-requested delivery delay [21] - OEM sales increased by 92% to $394,000, driven by strong shipments to Fluxer OEMs and new optics-related OEM wins [21] Market Data and Key Metrics Changes - U.S.-Canada sales decreased by 22% year over year, driven by slowing momentum in the clean energy industry [20] - Sales in Asia increased by 153% year over year, with major growth in China and other parts of Asia [20] - EMEA sales increased by 25%, while Latin America sales decreased by $74,000 [21] Company Strategy and Development Direction - The company has shifted to offering larger, more complex systems, which has broadened its addressable market and increased average unit selling prices [9][16] - The diversification strategy has shown momentum in the medical device industry, offsetting declines in clean energy orders [14][27] - Investments in R&D and application engineering are aimed at enhancing customer partnerships and driving long-term growth [64][66] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, supported by a solid backlog of $11,200,000 and a strong balance sheet with $10,600,000 in cash and no debt [15][26] - The company anticipates modest revenue growth for the full fiscal year, balancing caution with expected demand from the medical device industry [15][27] - Management noted that the clean energy sector is expected to decline this year, but diversification efforts are expected to mitigate this impact [14][27] Other Important Information - The company reported a gross profit margin increase to 50% for the second quarter, attributed to a favorable product mix and reduced costs [29][30] - The company has invested $1,300,000 in R&D for the first half of fiscal year 2026, compared to $1,400,000 in the previous year [26][34] - The company maintains a strong cash position with no outstanding debt, allowing for continued investment in growth initiatives [37] Q&A Session Summary Question: Insights on medical device strength and Chinese exposure - Management noted that despite challenges in the Chinese market, significant orders have been captured due to superior quality compared to local competitors [42][45] Question: Details on new optics-related OEMs - Management indicated that these new partnerships are significant for long-term market entry, although immediate revenue impact may be limited [76] Question: Semiconductor market outlook - Management reported strong interest from customers at a recent trade show, indicating potential growth in the semiconductor sector [79] Question: Backlog revenue recognition timeframe - The majority of recent large orders will be recognized in FY 2027, with some expected to ship in the current fiscal year [87] Question: Projections for second half sales - Management expects Q3 to be slightly higher than Q4 due to a system shipment delay [90]